Chronobiology international
-
New information has become available since the ISC, AAMCC, and SECAC released their first extensive guidedelines to improve the diagnosis and treatment of adult arterial hypertension. A critical assessment of evidence and a comparison of what international guidelines now propose are the basis for the following statements, which update the recommendations first issued in 2013. Office blood pressure (BP) measurements should no longer be considered to be the "gold standard" for the diagnosis of hypertension and assessment of cardiovascular risk. ⋯ In high-risk patients, including those diagnosed with diabetes or chronic kidney disease, and/or those having experienced past cardiovascular events, the thresholds are even lower by 15/10 mmHg, i.e., 105/60 mmHg. Bedtime treatment with the full daily dose of ≥1 hypertension medications is recommended as a cost-effective means to improve the management of hypertension and reduce hypertension-associated risk. Bedtime treatment entailing the full daily dose of ≥1 conventional hypertension medications must be the therapeutic regimen of choice for the elderly and those with diabetes, resistant and secondary hypertension, chronic kidney disease, obstructive sleep apnea, and medical history of past cardiovascular events, among others, given their documented high prevalence of sleep-time hypertension.
-
In a study published in Cancer Causes & Control in 2010, Kloog with co-authors tested, apparently for the first time, the association between population-level ambient exposure to artificial light at night (ALAN) and incidence of several cancers in women from 164 countries worldwide. The study was based on 1996-2002 data and concluded that breast cancer (BC) incidence was significantly and positively associated with ALAN, while no such association was revealed for other cancer types. An open question, however, remains whether the trends revealed by Kloog and co-authors were time specific or also hold true for more recent data. ⋯ However, when the entire sample of countries was disaggregated into geographic clusters of similarly developed countries, a positive BC-ALAN association re-emerged as statistically significant (t > 2.2; p < 0.01), helping to explain, along with other factors covered by the analysis, about 65-85% of BC ASR variability worldwide, depending on the model type. Although the present analysis reconfirms a positive BC-ALAN association, this association appeared to diverge regionally in recent years, with countries in Western Europe showing the highest levels of such association, while countries in Southeast Asia and Gulf States exhibiting relatively low BC rates against the backdrop of relatively high ALAN levels. This regional stratification may be due to additional protective mechanisms, diminishing BC risks and potentially attributed to the local diet and lifestyles.